iRegene's NouvNeu001 Becomes First iPSC Therapy to Receive Both FDA Fast Track and RMAT Designations for Parkinson's Disease
核心洞察
iRegene Therapeutics (搜索) announced that NouvNeu001 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, making it the first allogeneic iPSC-derived cell therapy globally to hold both RMAT and Fast Track designations for Parkinson's disease (搜索) treatment.
Phase I clinical data demonstrated significant motor function improvements, with the low-dose cohort showing 30.6 points improvement in MDS-UPDRS Part III scores (52.82% improvement from baseline) at 12 months, with sustained benefits observed through 15 months post-treatment.
The RMAT designation provides accelerated regulatory pathways and priority review eligibility, potentially shortening the timeline from clinical development to market for this disease-modifying dopaminergic progenitor cell therapy.
iRegene Therapeutics (搜索) Co., Ltd. announced that its lead product NouvNeu001 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration for treating Parkinson's disease (搜索). This regulatory milestone makes NouvNeu001 the first allogeneic iPSC-derived cell therapy globally to hold both FDA Fast Track Designation and RMAT designations, following the Fast Track Designation granted in August 2025.
The RMAT designation, established under the 21st Century Cures Act, accelerates development and review of regenerative medicine therapies for serious or life-threatening diseases. Products with RMAT designation receive benefits including early and frequent FDA interaction, potential eligibility for accelerated approval pathways, and priority review.
Addressing Unmet Medical Need in Parkinson's Disease
Parkinson's disease (搜索) represents the second most prevalent neurodegenerative disorder globally, with existing therapies primarily focusing on symptomatic relief rather than disease modification. NouvNeu001 was developed as an iPSC-derived, allogeneic dopaminergic progenitor cell therapy designed to replace lost dopaminergic neurons (搜索), restore disrupted neural circuits, and enable patients to regain endogenous dopamine production.
Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics (搜索), stated: "The RMAT designation is a pivotal regulatory advancement for NouvNeu001 and a strong endorsement of its clinical value. This designation reflects the FDA's recognition of NouvNeu001's potential to address a serious unmet medical need in Parkinson's disease (搜索) and provides a structured framework for deep, efficient collaboration with the agency."
Phase I Clinical Results Demonstrate Significant Efficacy
The Phase I clinical data revealed significant improvements in MDS-UPDRS Part III motor scores, the gold standard for assessing motor function in Parkinson's disease (搜索). The low-dose cohort showed improvements of 30.6 points in the OFF state (52.82% improvement from baseline) and 12.9 points in the ON state (54.67% improvement from baseline) at 12 months. The high-dose cohort demonstrated improvements of 23.3 points (OFF state) and 9.67 points (ON state) at 9 months.
These improvements were statistically significant, with continued improvement observed through 15 months post-treatment, suggesting sustained benefit from the engrafted cells. The results validate iRegene's chemical induction platform and the therapy's potential to modify disease progression.
Expanding Pipeline Across Neurodegenerative Diseases
iRegene is leveraging its "AI + Chemical Induction" platform to build a robust pipeline of universal iPSC-derived therapies. The company's expanding portfolio includes:
NouvNeu004 (搜索) recently received I-III all-stage IND approval from the NMPA, making it the world's first cell therapy product for Multiple System Atrophy (搜索) and iRegene's third self-developed product to enter clinical trials.
NouvNeu003 targets early-onset Parkinson's disease (搜索) and entered Phase I trials in December 2023 as the company's second product.
NouvSight001 represents a breakthrough ophthalmology product that received Orphan Drug Designation from the U.S. FDA in March 2024 for retinal degenerative diseases (搜索).
Chemical Induction Platform Technology
Founded in 2017, iRegene Therapeutics (搜索) pioneered the application of chemical induction to precisely reprogram cell fate and optimize cellular functions for innovative cell therapy products. The company's proprietary system enables efficient generation of human-specific cell types with high purity and enhanced cellular functionality, positioning it as a leader in chemically derived cell therapies for currently incurable diseases including Parkinson's disease (搜索) and blindness.